Clinical Trials Logo

Portal Vein Tumor Thrombus clinical trials

View clinical trials related to Portal Vein Tumor Thrombus.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04618367 Completed - Clinical trials for Carcinoma, Hepatocellular

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein tumor thrombus.

NCT ID: NCT01850368 Completed - Clinical trials for Hepatocellular Carcinoma

Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion

Start date: October 2012
Phase: Phase 2
Study type: Interventional

Recently, several studies reported promising outcomes of patients after external beam radiotherapy (EBRT) for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis. However, conventional EBRT is composed of many fractions (20-35 fractions). On the other hand, stereotactic ablative radiotherapy is a newly emerging treatment method to deliver a high dose of radiation to the target using a few fractions with a high precision within body. SABR increases radiation biologic effect for tumor, makes patients more comfortable due to reduction of the number of hospital visit, and enables patients to receive another treatment more quickly. This study will evaluate SABR effect with 40 Gy in 4 fractions for HCC with major portal vein tumor thrombosis.

NCT ID: NCT00849264 Completed - Clinical trials for Hepatocellular Carcinoma

Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients

Start date: December 2008
Phase: Phase 2
Study type: Interventional

This study is working to evaluate the surgical comprehensive treatment for different types of tumor thrombi in the portal vein for hepatocellular carcinoma patients, to establish a standardized, unified, effective therapeutic program.